Published in Dement Geriatr Cogn Disord on January 11, 2000
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain (2006) 1.86
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med (2012) 0.85
Brain activation in offspring of AD cases corresponds to 10q linkage. Ann Neurol (2005) 0.85
Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease. J Neuroinflammation (2014) 0.78
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med (1998) 2.68
The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med (1995) 2.44
Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet (1992) 2.32
Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med (1999) 2.03
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry (2000) 1.97
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology (2011) 1.81
Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology (1999) 1.78
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Impaired insulin secretion increases the risk of Alzheimer disease. Neurology (2008) 1.76
Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest (1997) 1.74
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron (1995) 1.56
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Ammonia, a selective agent for methane production by syntrophic acetate oxidation at mesophilic temperature. Water Sci Technol (2008) 1.52
Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging (2000) 1.49
Aluminosis and dementia. Lancet (1994) 1.43
Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord (1997) 1.42
Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med (1997) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 1.37
[More accurate diagnosis could identify patients suitable for tacrine therapy]. Lakartidningen (1996) 1.37
Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol (2000) 1.37
Lifestyle, obesity, and insulin resistance. Diabetes Care (2001) 1.36
Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A (1994) 1.31
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology (2002) 1.30
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet (1996) 1.26
Distinct B cell subpopulations differ in their genetic requirements for activation by T helper cells. Immunol Rev (1982) 1.26
No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol (1997) 1.25
T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies. J Exp Med (1982) 1.24
High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res (2010) 1.23
A method for demonstrating gene essentiality in Staphylococcus aureus. Plasmid (2000) 1.23
Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem (2000) 1.23
Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci U S A (1995) 1.22
White-matter hyperintensity and neuropsychological functions in dementia and healthy aging. Arch Neurol (1992) 1.22
Image distortion in rotational panoramic radiography. II. Vertical distances. Acta Radiol Diagn (Stockh) (1981) 1.21
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat (2001) 1.20
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry (2012) 1.20
Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men. Diabetologia (2009) 1.19
Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity. J Exp Med (1984) 1.18
Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res (1993) 1.17
Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med (1995) 1.16
Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect (1993) 1.15
DNA polymorphisms within the porphobilinogen deaminase gene in two Swedish families with acute intermittent porphyria. Hum Genet (1988) 1.13
Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol (1996) 1.12
Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Arch Neurol (1996) 1.11
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol (1999) 1.11
Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect (1992) 1.11
Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res (1999) 1.11
Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging (2006) 1.11
Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol (2000) 1.11
Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord (2000) 1.10
A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: no role in the genetic predisposition to bipolar affective disorder. Psychiatry Res (1993) 1.10
Brain activation in young and older adults during implicit and explicit retrieval. J Cogn Neurosci (1997) 1.09
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.09
Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med (2000) 1.09
Postnatal changes of nicotinic acetylcholine receptor alpha 2, alpha 3, alpha 4, alpha 7 and beta 2 subunits genes expression in rat brain. Int J Dev Neurosci (1998) 1.07
Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med (2014) 1.07
Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res (1999) 1.06
Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. J Mol Biol (2004) 1.06
On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett (2001) 1.05